GALERA THERAPEUTICS, INC.

Analyst Reco. Galera Therapeutics, Inc.

Equities

GRTX

US36338D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
0.107 ^USD	-6.96%		-45.41%	-26.41%

Jun. 03	Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May	MT
Jun. 03	Top Premarket Decliners	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Galera Therapeutics to Neutral From Buy, Adjusts Price Target to $0.30 From $6	23-08-16	MT
Piper Sandler Downgrades Galera Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.50 From $6	23-08-10	MT
HC Wainwright Adjusts Galera Therapeutics Price Target to $6 From $10, Maintains Buy Rating	23-03-22	MT
Piper Sandler Starts Galera Therapeutics at Overweight With $6 Price Target	23-02-21	MT
BofA Securities Upgrades Galera Therapeutics to Buy From Underperform, Adjusts Price Target to $7 From $2	23-02-16	MT
BofA Securities Downgrades Galera Therapeutics to Underperform From Neutral, Sets Price Target at $2	22-05-27	MT
Citigroup Adjusts Galera Therapeutics' Price Target to $20 From $11, Reiterates Buy Rating	21-12-20	MT
HC Wainwright Upgrades Galera Therapeutics to Buy From Neutral; Price Target is $10	21-12-15	MT
BofA Securities Upgrades Galera Therapeutics to Neutral From Underperform, Adjusts Price Target to $4 From $2	21-12-15	MT
BTIG Upgrades Galera Therapeutics to Buy From Neutral; Price Target is $15	21-12-15	MT
Galera Therapeutics Extends Gains in Pre-Market Following Ratings Upgrades from BTIG, BofA Securities	21-12-15	MT
Today on Wall Street: Earnings season, bitcoin and the metaverse	21-10-20
GALERA THERAPEUTICS : HC Wainwright Downgrades Galera Therapeutics to Neutral From Buy	21-10-20	MT
ANALYST RECOMMENDATIONS : BHP Group, Cloudflare, Tesla, Microsoft, Target...	21-10-20
GALERA THERAPEUTICS : BTIG Downgrades Galera Therapeutics to Neutral from Buy	21-10-19	MT
GALERA THERAPEUTICS : Credit Suisse Upgrades Galera Therapeutics to Outperform from Neutral on Positive Proof of Concept Data, Adjusts Price Target to $15 from $9	20-12-16	MT
GALERA THERAPEUTICS : Credit Suisse Upgrades Galera Therapeutics to Outperform From Neutral, Adjusts Price Target to $15 From $9	20-12-16	MT
GALERA THERAPEUTICS : HC Wainwright Starts Galera Therapeutics at Buy With $15 Price Target	20-12-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer